BeOne Medicines Sells Royalties to Royalty Pharma for Up to $950 Million.

BeOne Medicines has sold Imdelltra royalties to Royalty Pharma for up to $950 million. BeiGene, a biotechnology company, is developing oncology treatments worldwide and has three approved medicines, including BRUKINSA, TEVIMBRA, and pamiparib. The company has obtained approvals to market these treatments in various international markets, including the US, EU, China, and Australia.

Royalty Pharma has agreed to purchase the royalty rights on Amgen's cancer drug Imdelltra from BeOne Medicines for up to $950 million. Imdelltra, an immunotherapy drug approved in the US for certain cancer patients, is expected to generate significant revenue for Royalty Pharma over the next 12 to 15 years.

The deal involves an upfront payment of $885 million, with an option for BeOne to sell an additional portion of its royalty to Royalty Pharma for up to $65 million within the next 12 months. Royalty Pharma will receive payments based on approximately 7% of Imdelltra’s worldwide net sales, excluding China, over the specified period [1].

Imdelltra, which received accelerated FDA approval in May 2024 for the treatment of extensive-stage small cell lung cancer (ES-SCLC), has shown promising sales results. In the first half of 2025, sales reached $215 million, and analysts project sales to exceed $2.8 billion by 2035 [2].

This acquisition aligns with Royalty Pharma’s strategy of investing in highly transformative products in the life sciences sector. The company expects Imdelltra to enhance its long-term growth and portfolio diversification. BeOne Medicines, on the other hand, will strengthen its balance sheet and unlock substantial value, providing increased operational and strategic flexibility to continue executing its mission [1].

The transaction is significant for both companies. Royalty Pharma's robust transaction pipeline and collaboration with innovators from academic institutions, research hospitals, and leading pharmaceutical companies make this acquisition part of its ongoing strategy to fund innovation in the biopharmaceutical industry [1].

References:
[1] https://www.royaltypharma.com/news/royalty-pharma-to-acquire-royalty-interest-in-amgens-imdelltra-for-up-to-950-million/
[2] https://www.nasdaq.com/articles/royalty-pharma-acquires-royalty-interest-imdelltra-beone